Ikarisoside F



Compound IDCDAMM01508
Common nameIkarisoside F
IUPAC name3-[4,5-dihydroxy-6-methyl-3-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]oxy-5,7-dihydroxy-2-(4-hydroxyphenyl)-8-(3-methylbut-2-enyl)chromen-4-one
Molecular formulaC31H36O14

Experimental data

Retention time8.42
Adduct[M+H]+
Actual mz633.21
Theoretical mz633.218
Error12.44
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score6.2761

Identifiers and class information

Inchi keyASPIQZXMZNLGRL-FCBGNLNSNA-N
SmilesO=C1C(OC2OC(C)C(O)C(O)C2OC3OCC(O)C(O)C3O)=C(OC=4C1=C(O)C=C(O)C4CC=C(C)C)C=5C=CC(O)=CC5
SuperclassPhenylpropanoids and polyketides
ClassFlavonoids

Pharmacokinetic properties

Number of descriptor values(#stars)6
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)14
Number of reactive functional groups (#rtvFG)2
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)632.617
Computed dipole moment(dipole)3.21
Total solvent accessible surface area (SASA)823.413
Hydrophobic component of SASA (FOSA)396.074
Hydrophilic component of SASA (FISA)281.914
Pie component of the SASA (PISA)145.425
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1657.54
Number of hydrogen bond donors (donorHB)7
Number of hydrogen bond acceptors (accptHB)18.1
Free energy of solvation of dipole (dip^2/V)0.0062171
Index of cohesive interaction in solids (ACxDN^.5/SA)0.058158
Globularity descriptor (glob)0.822604
Predicted polarizability in cubic angstroms (QPpolrz)52.58
Predicted hexadecane/gas partition coefficient (QPlogPC16)18.021
Predicted octanol/gas partition coefficient (QPlogPoct)38.086
Predicted water/gas partition coefficient (QPlogPw)29.6
Predicted octanol/water partition coefficient (QPlogPo/w)-0.006
Predicted aqueous solubility (QPlogS)-3.067
Conformation-independent predicted aqueous solubility (CIQPlogS)-5.558
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-5.096
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)21.014
Predicted brain/blood partition coefficient (QPlogBB)-3.058
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)7.606
Predicted skin permeability, log Kp (QPlogKp)-4.859
PM3 calculated ionization potential (IP(ev))8.73
PM3 calculated electron affinity (EA(eV))0.411
Number of likely metabolic reactions (#metab)11
Prediction of binding to human serum albumin (QPlogKhsa)-0.777
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)11.705
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)213.487
Number of nitrogen and oxygen atoms (#NandO)14
Number of violations of Lipinski’s rule of five (RuleOfFive)3
Number of violations of Jorgensen’s rule of three (RuleOfThree)2

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
O43570CA12Carbonic anhydrase XIIT16987SwissTargetPrediction
P19838NFKB1Nuclear factor NF-kappa-B p105 subunitT83145SEA
P43166CA7Carbonic anhydrase VIIT37541SwissTargetPrediction
P22748CA4Carbonic anhydrase IVT53378SwissTargetPrediction
P15121AKR1B1Aldose reductaseT26623SwissTargetPrediction
O76074PDE5APhosphodiesterase 5AT07663SwissTargetPrediction
P60568IL2Interleukin-2T61698SEA
Q9UNQ0ABCG2ATP-binding cassette sub-family G member 2T56556SEA
P14679TYRTyrosinaseT97035SEA
Q9NPH5NOX4NADPH oxidase 4T29741SEA
Q9GZQ4NMUR2Neuromedin-U receptor 2T04210SEA
P30837ALDH1B1Acetaldehyde dehydrogenaseT99641SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T16987DI0046Bacterial infection[ICD-11: 1A00-1C4Z]O43570CA12
T16987DI0372Seborrhoeic dermatitis[ICD-11: EA81]O43570CA12
T83145DI0218Irritable bowel syndrome[ICD-11: DD91]P19838NFKB1
T83145DI0366Rheumatoid arthritis[ICD-11: FA20]P19838NFKB1
T53378DI0046Bacterial infection[ICD-11: 1A00-1C4Z]P22748CA4
T53378DI0166Glaucoma[ICD-11: 9C61]P22748CA4
T53378DI0372Seborrhoeic dermatitis[ICD-11: EA81]P22748CA4
T26623DI0298Neuropathy[ICD-11: 8C0Z]P15121AKR1B1
T26623DI0366Rheumatoid arthritis[ICD-11: FA20]P15121AKR1B1
T07663DI0190Hypertension[ICD-11: BA00-BA04]O76074PDE5A
T07663DI0213Innate/adaptive immunodeficiency[ICD-11: 4A00]O76074PDE5A
T07663DI0378Sexual dysfunction[ICD-11: HA00-HA01]O76074PDE5A
T07663DI0411Tonus and reflex abnormality[ICD-11: MB47]O76074PDE5A
T61698DI0275Multiple sclerosis[ICD-11: 8A40]P60568IL2
T61698DI0361Renal cell carcinoma[ICD-11: 2C90]P60568IL2
T56556DI0218Irritable bowel syndrome[ICD-11: DD91]Q9UNQ0ABCG2
T56556DI0366Rheumatoid arthritis[ICD-11: FA20]Q9UNQ0ABCG2
T97035DI0007Acquired hypermelanosis[ICD-11: ED60]P14679TYR
T97035DI0008Acquired hypomelanotic disorder[ICD-11: ED63]P14679TYR
T29741DI0146Fibrosis[ICD-11: GA14-GC01]Q9NPH5NOX4
T99641DI0396Substance abuse[ICD-11: 6C40]P30837ALDH1B1

Copyright © 2025